摘要
目的探讨米非司酮对子宫肌瘤组织中细胞核增殖抗原ki-67表达的影响。方法共纳入有子宫切除指征的子宫肌瘤病人60例,随机分为实验组32例,对照组28例。实验组病人每天口服米非司酮100mg共5d,第六天手术;对照组病人入院后不服用任何药物,直接手术。手术后采用免疫组化方法 ,检测两组手术标本中子宫肌瘤组织和相应的子宫肌层组织ki-67阳性细胞百分率。结果实验组子宫肌瘤组织中ki-67阳性率〔(5.31±3.92)%〕,对照组〔(8.43±2.82)%〕,差异有统计学意义;两组子宫肌层组织中ki-67阳性率无显著性差异。结论米非司酮抑制子宫肌瘤细胞增殖,这可能是非司酮治疗子宫肌瘤的作用机理之一。
OBJECTIVE To investigate the expression of Proliferating Cell Nuclear Antigen ki-67 by Mifepristone in uterine leiomyoma smooth muscle tissues. METHODS A total of 60 women with uterine leiomyomas scheduled for surgical intervention were randomly, divided into experimental group （32 cases） and control group （28 cases）. The experimental group were receive 100mg Mifepristone for 5 days before surgery and control group were operated directly. Immunohistochemical methods to investigate the expression of ki-67 in uterine leiomyoma smooth muscle tissues and uterine smooth muscle tissues. RESULTS The positive rate of ki-67 expressing in uterine leiomyoma smooth muscle tissues in experimental group of was （8.43 ±2. 82）%, which was （5.31 ± 3.92）% in control group. The different was statistically significant. The expression of ki-67 in uterine smooth muscle tissues were similar between the two groups. CONCLUSION Mifepristone may offer an effective treatment option for women with uter- ine leiomyoma by inhibiting the proliferation in uterine leiomyoma smooth muscle.
出处
《海峡药学》
2013年第12期191-192,共2页
Strait Pharmaceutical Journal
基金
海南省卫生厅基金资助项目(编号:2010-30)
关键词
子宫肌瘤
米非司酮
KI-67
Uterine leiomyoma
Mifepristone
Proliferadng cell nuclear antigen ki-67
